Literature DB >> 14970167

Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.

Fadi Fakhouri, Luis Teixeira, Richard Delarue, Jean-Pierre Grünfeld, Agnès Veyradier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14970167     DOI： 10.7326/0003-4819-140-4-200402170-00028

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  7 in total

1.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

2.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

3.  Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.

Authors:  D Li; J Xiao; M Paessler; X L Zheng
Journal:  Thromb Haemost       Date:  2011-09-08       Impact factor: 5.249

Review 4.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

5.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

6.  Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy.

Authors:  Faisal Musa; Said Baidas
Journal:  Case Rep Oncol       Date:  2015-04-22

7.  An improbable and unusual case of thrombotic thrombocytopenia purpura.

Authors:  Jaymon Patel; Preeti Patel; Zohair Ahmed
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.